Our goal is to drive returns through revenue-generating licensing deals for our high value assets with the pharmaceutical industry, which will be reinvested into our Drug Discovery portfolio to maximise value for shareholders.
The need for high quality, oral, small molecule drugs to improve treatment standards in immuno-inflammation diseases continues to grow. We are poised to address this opportunity with a strong portfolio of high commercial potential assets.
Following programme initiation, we apply our discovery expertise to generate high quality data packages which demonstrate the potential of our compounds to progress into clinical studies.
The pharma industry focus is constantly evolving in the search for new innovative drugs for diseases with no current treatments or where treatments exist but provide inadequate efficacy, safety or dosing.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.